PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Differential Expression of IGF-I Transcripts in Bladder Cancer.

Abstract A growing body of evidence shows that the differential expression of E domain-related insulin-like growth factor-I (IGF-I) transcripts (IFG-IEa, IGF-IEb and IGF-IEc) in normal and cancerous tissues, implicating specific biological roles for the putative Ea, Eb, and Ec peptides, beyond IGF-I. Herein, we investigated the expression profile of IGF-IEa, IGF-IEb and IGF-IEc transcripts in bladder cancer and compared them with samples from the normal adjacent bladder tissue.
PMID
Related Publications

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer.

Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C.

Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer.

Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue.

The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity.

Authors

Mayor MeshTerms

Alternative Splicing

Gene Expression Regulation, Neoplastic

Keywords

IGF-IEa

IGF-IEb

IGF-IEc

Insulin-like growth factor I

bladder cancer

Journal Title anticancer research
Publication Year Start




PMID- 29848696
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180611
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 6
DP  - 2018 Jun
TI  - Differential Expression of IGF-I Transcripts in Bladder Cancer.
PG  - 3453-3459
LID - 10.21873/anticanres.12614 [doi]
AB  - BACKGROUND/AIM: A growing body of evidence shows that the differential expression
      of E domain-related insulin-like growth factor-I (IGF-I) transcripts (IFG-IEa,
      IGF-IEb and IGF-IEc) in normal and cancerous tissues, implicating specific
      biological roles for the putative Ea, Eb, and Ec peptides, beyond IGF-I. Herein, 
      we investigated the expression profile of IGF-IEa, IGF-IEb and IGF-IEc
      transcripts in bladder cancer and compared them with samples from the normal
      adjacent bladder tissue. MATERIALS AND METHODS: Biopsies from 46 patients (39 men
      and 7 women), aged 73.3+/-10.9 years, were analyzed for the expression of IGF-I
      transcripts using semi-quantitative real time-PCR (qRT-PCR). RESULTS: The
      presence of all three IGF-I transcripts was detected in both normal urothelium
      and bladder carcinomas. The relative expression of the IGF-IEa and IFG-IEb was
      marginally increased in bladder cancer tissues compared to normal tissue
      (p>0.05). In contrast, the expression of the IGF-IEc was significantly decreased 
      in bladder cancer as compared to normal adjacent urothelium (p<0.05). This
      specific suppression of IGF-IEc expression was evident and positively correlated 
      with the histological and/or clinical characteristics of an advanced disease,
      referring to clinical stage, tumor grade and disease recurrence (p<0.05);
      however, in situ carcinomas exhibited an increased expression of all IGF-I
      transcripts. CONCLUSION: Our data confirm the differential expression of IGF-I
      transcripts in bladder cancer, revealing a distinct suppression of IGF-IEc. These
      findings suggest that IGF-IEc expression and putative Ec product may possess
      discrete biological role in disease progression beyond IGF-I.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Mourmouras, Nikos
AU  - Mourmouras N
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Athens, Greece.
FAU - Philippou, Anastassios
AU  - Philippou A
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Athens, Greece.
FAU - Christopoulos, Panagiotis
AU  - Christopoulos P
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Athens, Greece.
FAU - Kostoglou, Katerina
AU  - Kostoglou K
AD  - Department of Surgery, "Asklepieion" General Hospital, Athens, Greece.
FAU - Grivaki, Christofora
AU  - Grivaki C
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Athens, Greece.
FAU - Konstantinidis, Charalampos
AU  - Konstantinidis C
AD  - Urology Clinic, "Asklepieion" General Hospital, Athens, Greece.
FAU - Serafetinides, Efraim
AU  - Serafetinides E
AD  - Urology Clinic, "Asklepieion" General Hospital, Athens, Greece.
FAU - Delakas, Dimitrios
AU  - Delakas D
AD  - Urology Clinic, "Asklepieion" General Hospital, Athens, Greece.
FAU - Koutsilieris, Michael
AU  - Koutsilieris M
AD  - Department of Physiology, Medical School, National and Kapodistrian University of
      Athens, Athens, Greece [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (RNA Isoforms)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Alternative Splicing
MH  - Female
MH  - Gene Expression Profiling/*methods
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Insulin-Like Growth Factor I/*genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local
MH  - Neoplasm Staging
MH  - RNA Isoforms/*genetics
MH  - Urinary Bladder Neoplasms/*genetics/pathology
OTO - NOTNLM
OT  - IGF-IEa
OT  - IGF-IEb
OT  - IGF-IEc
OT  - Insulin-like growth factor I
OT  - bladder cancer
EDAT- 2018/06/01 06:00
MHDA- 2018/06/12 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/04/13 00:00 [received]
PHST- 2018/05/10 00:00 [revised]
PHST- 2018/05/11 00:00 [accepted]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
AID - 38/6/3453 [pii]
AID - 10.21873/anticanres.12614 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jun;38(6):3453-3459. doi: 10.21873/anticanres.12614.